

## **EXECUTIVE TEAM**

### **Magnus Medical, Inc.**

#### **Dave Vort** **President**

Dave Vort joined Magnus Medical as president in March 2023, bringing with him over 25 years of experience driving organizational and commercial impact with Fortune 500 and startup healthcare organizations. Before coming to Magnus, Mr. Vort held the position of chief commercial officer for iRhythm Technologies, Inc., a leading cardiovascular diagnostics and digital healthcare solutions company that went public on the NASDAQ in 2016. Prior to this role, Mr. Vort served as vice president of U.S. sales at InTouch Health, a provider of telemedicine and remote presence solutions that was later acquired by Teledoc, and as area vice president for Intuitive Surgical, where he led the 90-member Western U.S. team through significant growth and expansion. His other past tenures include extensive international experience leading business units for Stryker and the Global Healthcare Exchange, where he was a member of the founding team that ultimately sold the company to a coalition led by GE, J&J, and Medtronic.

Mr. Vort received his Bachelor of Arts in Political Science from the University of the Pacific.

#### **Brandon Bentzley, M.D., Ph.D.** **Co-founder and Chief Scientific Officer**

Brandon Bentzley, M.D., Ph.D., is co-founder and chief scientific officer of Magnus Medical. His interest in neuroscience led him to begin the Medical Scientist Training Program at the Medical University of South Carolina (MUSC), which is the birthplace of clinical transcranial magnetic stimulation (TMS) for the treatment of neuropsychiatric disorders. At MUSC, he completed his dissertation research with Gary Aston-Jones, Ph.D., studying the behavioral economics and neuroeconomics of substance use disorders. Simultaneously, he conducted clinical research on buprenorphine maintenance therapy, focusing on how patient perspectives influence treatment. He completed his residency in adult psychiatry and his postdoctoral training at Stanford University, where he focused on the development of SAINT technology. Dr. Bentzley has published articles in high-impact peer-reviewed journals, including *Brain*, *American Journal of Psychiatry*, *Molecular Psychiatry*, *Biological Psychiatry*, *Journal of Neuroscience*, *Journal of the American Medical Association Network Open*, and *Proceedings of the National Academy of Sciences of the United States of America*.

In parallel with his clinical work, Dr. Bentzley has over 15 years of experience in developing advanced automated systems that range from plasma reactors used in variable gravity

experiments at NASA to high-powered magnetically confined plasma reactors at Princeton University. He has developed and built a highly advanced neuro-behavioral recording system, which is currently in full-time use at the Malenka Lab in the Department of Psychiatry at Stanford Medicine.

Dr. Bentzley received a Bachelor of Science in Physics from The College of New Jersey and his M.D. and Ph.D. from MUSC. His academic appointments include Clinical Assistant Professor in Psychiatry and Behavioral Sciences at Stanford University School of Medicine. His areas of clinical focus are treatment-resistant depression, substance abuse disorders, and suicidality.

**Huyen Duong**  
**Vice President of Regulatory Affairs and Quality Assurance**

Huyen Duong joined Magnus Medical as vice president of regulatory affairs and quality assurance, contributing over 25 years of experience in quality assurance and regulatory affairs for startups and established medical technology companies. Prior to joining Magnus, she was vice president of regulatory affairs and quality assurance at Nesos Corporation, an early-stage startup where she was responsible for defining regulatory and clinical strategies to support global commercialization of Nesos' non-invasive neuromodulation platform for the treatment of migraines, rheumatoid arthritis and postpartum depression. Previously, Ms. Duong was the senior director of regulatory affairs and clinical operations for Nevro Corporation, where she supported pre and post-market regulatory activities and the conduct of more than 20 new and ongoing clinical investigations while managing clinical operational processes to guarantee compliance with the U.S. FDA and international requirements for carrying out clinical trials. She has also held senior management positions in regulatory affairs at Boston Neuromodulation and Bausch and Lomb.

Ms. Duong earned a Bachelor of Science in Biological Sciences from the University of California, Irvine.

**Sarah Keenan**  
**Vice President of Commercial Enablement**

Sarah Keenan joined Magnus Medical as vice president of commercial enablement contributing over 15 years of experience in medical device commercialization for both start-ups and mid-sized multinational companies. Prior to joining Magnus, she was vice president of commercial enablement at iRhythm Technologies, where she was responsible for ensuring U.S. and international commercial team members had the required knowledge, resources, and skills to optimize results. Ms. Keenan built the commercial enablement function from the ground up and was a core team member in taking iRhythm from a start-up to a mid-sized company. Previously, she was the national sales training

manager and a genomic sales specialist for CardioDx, where she helped to launch Corus CAD and scale training capabilities for the sales organization. Ms. Keenan has also held sales positions at ThermoFisher Scientific (PhadiaAB), Merz Pharmaceuticals, Schering-Plough and Altria Group.

Ms. Keenan earned a Bachelor of Science in Business Administration from the University of Illinois Gies School of Business.

**Romain Moreau-Gobard**  
**Vice President of Software Engineering**

Romain Moreau-Gobard joined Magnus Medical as vice president of software engineering, contributing over 20 years of experience in the development of advanced medical imaging software for both startups and established multinational companies. Before joining Magnus, he was vice president of software engineering for Advanced Scanners, where he led the development of 3D reconstruction and imaging algorithms for a novel structured light scanner for brain and spine imaging. Prior to this, Mr. Moreau-Gobard led software engineering teams at HeartFlow, where he designed a novel SAMD (software as a medical device) product to determine the fractional flow reserve from cardiac computed tomography (CT) scans, allowing entirely non-invasive detection and diagnosis of heart disease. HeartFlow's software received U.S. Food & Drug Administration (FDA) clearance in 2014, and in 2021, the company announced it would go public with a valuation of \$2.4 billion. Mr. Moreau-Gobard has also held engineering leadership roles at Siemens Medical and Siemens Corp. Technology.

Mr. Moreau-Gobard received a Master of Science in Artificial Intelligence from EPITA, the School of Engineering and Computer Science in Paris, France, and a Master of Science in Management of Information Systems from Stevens Institute of Technology. He currently holds 15 U.S. and international patents.

**Tammy Morton**  
**Vice President of Clinical Affairs**

Tammy Morton brings more than 20 years of experience in planning and executing clinical trials to support regulatory submissions for class II and class III medical devices in a variety of therapeutics for both large corporations and startups. Ms. Morton has consulted for Magnus Medical since May 2021, providing expertise in clinical trial strategy, planning, and execution of studies, and in January 2022, she joined the company as its vice president of clinical affairs. Before joining Magnus full-time, Ms. Morton was also the head of clinical affairs for CapsoVision, Inc., where she implemented the study design, operational planning, and execution for future regulatory approval of a colon capsule endoscope. Prior to joining CapsoVision, Ms. Morton was vice president of clinical affairs for Halo Neuroscience, the developer of home-use neurostimulation technology, where she was

instrumental in planning the company's clinical strategy for major depressive disorder. Before joining Halo, she was vice president of clinical affairs for Radial Medical, where she planned and executed pre-market clinical trials in deep vein thrombosis, venous leg ulcer, and restless legs syndrome therapeutics. Her previous tenures also include senior management positions in clinical affairs at Gynesonics, Abbott Vascular, and Bailer Research, as well as a clinical research instructor at the University of California, Santa Cruz.

Ms. Morton earned a Bachelor of Science in Zoology from the University of California, Davis, and a Master of Science in Exercise Physiology from California State University, Sacramento.

**Joost de Schutter**  
**Vice President of Finance**

Joost de Schutter joined Magnus Medical as vice president of finance, contributing over 25 years of experience in healthcare technology and life sciences for both Fortune 500 companies and startups. Most recently, Mr. de Schutter was vice president of finance for HeartFlow, where he successfully guided the company through its transition to public company readiness. Previously, he was vice president of finance for Thermo Fisher Scientific's Clinical Diagnostics Division, where he partnered with the global division's executive team to drive revenue growth and margin expansion while managing all aspects of the finance function. His previous tenures also include multiple senior management positions, including vice president, corporate controller for Prysm, consulting CFO for RenovoRX, an early-stage medical device start-up, and various finance leadership positions at Philips Healthcare.

Mr. de Schutter earned a Bachelor of Science in Business Economics from Erasmus University Rotterdam, and an international Executive Master of Finance and Control (iEMFC) from both the University of Maastricht, The Netherlands, and Washington University, St. Louis, receiving the Certified Controller title.

**Leslie Stephens**  
**Vice President of Reimbursement**

Leslie Stephens brings over 20 years of market access and reimbursement, marketing, and market development experience in the medical device industry to her role as vice president of reimbursement for Magnus Medical. Prior to joining Magnus, she was executive vice president of marketing for Elixir Medical, where she was responsible for developing a new therapy, the Coronary Bioadaptor stent technology. Before joining Elixir, Ms. Stephens was the vice president of global market access at HeartFlow, where she was responsible for strategic planning and market access. Previous experience also includes several leadership positions at Abbott Vascular, including director of health economics and reimbursement,

director of global marketing, and marketing director for the company's global core products. Ms. Stephens began her career in R&D for point-of-care diagnostics.

She earned a Bachelor of Arts in Biology from Kenyon College, a Master of Business Administration, and a Master of Public Health from the University of California, Berkeley.

# # #